IRIS Accounts Production v24.2.0.383 10123245 director 1.5.23 30.4.24 30.4.24 Consultancy false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh101232452023-04-30101232452024-04-30101232452023-05-012024-04-30101232452022-04-30101232452022-05-012023-04-30101232452023-04-3010123245ns15:EnglandWales2023-05-012024-04-3010123245ns14:PoundSterling2023-05-012024-04-3010123245ns10:Director12023-05-012024-04-3010123245ns10:PrivateLimitedCompanyLtd2023-05-012024-04-3010123245ns10:SmallEntities2023-05-012024-04-3010123245ns10:AuditExemptWithAccountantsReport2023-05-012024-04-3010123245ns10:SmallCompaniesRegimeForDirectorsReport2023-05-012024-04-3010123245ns10:SmallCompaniesRegimeForAccounts2023-05-012024-04-3010123245ns10:FullAccounts2023-05-012024-04-3010123245ns10:OrdinaryShareClass12023-05-012024-04-3010123245ns10:CompanySecretary12023-05-012024-04-3010123245ns10:RegisteredOffice2023-05-012024-04-3010123245ns5:CurrentFinancialInstruments2024-04-3010123245ns5:CurrentFinancialInstruments2023-04-3010123245ns5:ShareCapital2024-04-3010123245ns5:ShareCapital2023-04-3010123245ns5:RetainedEarningsAccumulatedLosses2024-04-3010123245ns5:RetainedEarningsAccumulatedLosses2023-04-3010123245ns5:ShareCapital2022-04-3010123245ns5:RetainedEarningsAccumulatedLosses2022-04-3010123245ns5:RetainedEarningsAccumulatedLosses2022-05-012023-04-3010123245ns5:RetainedEarningsAccumulatedLosses2023-05-012024-04-301012324512023-05-012024-04-3010123245ns5:ComputerEquipment2023-05-012024-04-3010123245ns5:ComputerEquipment2023-04-3010123245ns5:ComputerEquipment2024-04-3010123245ns5:ComputerEquipment2023-04-3010123245ns5:AdditionsToInvestments2024-04-3010123245ns5:CostValuation2024-04-3010123245ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-04-3010123245ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-04-3010123245ns10:OrdinaryShareClass12024-04-30
REGISTERED NUMBER: 10123245 (England and Wales)















Report of the Director and

Unaudited Financial Statements for the Year Ended 30 April 2024

for

SKM LIFE SCIENCES LIMITED

SKM LIFE SCIENCES LIMITED (REGISTERED NUMBER: 10123245)






Contents of the Financial Statements
for the year ended 30 April 2024




Page

Company Information 1

Report of the Director 2

Chartered Accountants' Report 3

Income Statement 4

Balance Sheet 5

Statement of Changes in Equity 6

Notes to the Financial Statements 7


SKM LIFE SCIENCES LIMITED

Company Information
for the year ended 30 April 2024







DIRECTOR: S K Morling





SECRETARY: L Morling





REGISTERED OFFICE: 11 Laura Place
Bath
Avon
BA2 4BL





REGISTERED NUMBER: 10123245 (England and Wales)





ACCOUNTANTS: Richardson Swift
Chartered Accountants
11 Laura Place
Bath
BA2 4BL

SKM LIFE SCIENCES LIMITED (REGISTERED NUMBER: 10123245)

Report of the Director
for the year ended 30 April 2024

The director presents his report with the financial statements of the company for the year ended 30 April 2024.

DIRECTOR
S K Morling held office during the whole of the period from 1 May 2023 to the date of this report.

STATEMENT OF DIRECTOR'S RESPONSIBILITIES
The director is responsible for preparing the Report of the Director and the financial statements in accordance with applicable law and regulations.

Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the director must not approve the financial statements unless he is satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the director is required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable him to ensure that the financial statements comply with the Companies Act 2006. He is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

ON BEHALF OF THE BOARD:





S K Morling - Director


19 August 2024

Chartered Accountants' Report to the Director
on the Unaudited Financial Statements of
SKM Life Sciences Limited


In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of SKM Life Sciences Limited for the year ended 30 April 2024 which comprise the Income Statement, Balance Sheet, Statement of Changes in Equity and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the director of SKM Life Sciences Limited in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of SKM Life Sciences Limited and state those matters that we have agreed to state to the director of SKM Life Sciences Limited in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than SKM Life Sciences Limited and its director for our work or for this report.

It is your duty to ensure that SKM Life Sciences Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of SKM Life Sciences Limited. You consider that SKM Life Sciences Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of SKM Life Sciences Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.






Richardson Swift
Chartered Accountants
11 Laura Place
Bath
BA2 4BL


20 August 2024

SKM LIFE SCIENCES LIMITED (REGISTERED NUMBER: 10123245)

Income Statement
for the year ended 30 April 2024

2024 2023
Notes £    £   

TURNOVER 2,625 -

Administrative expenses 9,558 2,739
OPERATING LOSS (6,933 ) (2,739 )

Interest receivable and similar income 17 -
LOSS BEFORE TAXATION (6,916 ) (2,739 )

Tax on loss 4 - -
LOSS FOR THE FINANCIAL YEAR (6,916 ) (2,739 )

SKM LIFE SCIENCES LIMITED (REGISTERED NUMBER: 10123245)

Balance Sheet
30 April 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 5 - -
Investments 6 10,000 -
10,000 -

CURRENT ASSETS
Debtors 7 2,627 1,245
Cash at bank 101,253 119,036
103,880 120,281
CREDITORS
Amounts falling due within one year 8 2,431 916
NET CURRENT ASSETS 101,449 119,365
TOTAL ASSETS LESS CURRENT
LIABILITIES

111,449

119,365

CAPITAL AND RESERVES
Called up share capital 9 100 100
Retained earnings 111,349 119,265
SHAREHOLDERS' FUNDS 111,449 119,365

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 April 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 April 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the director and authorised for issue on 19 August 2024 and were signed by:



S K Morling - Director


SKM LIFE SCIENCES LIMITED (REGISTERED NUMBER: 10123245)

Statement of Changes in Equity
for the year ended 30 April 2024

Called up
share Retained Total
capital earnings equity
£    £    £   
Balance at 1 May 2022 100 124,004 124,104

Changes in equity
Dividends - (2,000 ) (2,000 )
Total comprehensive income - (2,739 ) (2,739 )
Balance at 30 April 2023 100 119,265 119,365

Changes in equity
Dividends - (1,000 ) (1,000 )
Total comprehensive income - (6,916 ) (6,916 )
Balance at 30 April 2024 100 111,349 111,449

SKM LIFE SCIENCES LIMITED (REGISTERED NUMBER: 10123245)

Notes to the Financial Statements
for the year ended 30 April 2024

1. STATUTORY INFORMATION

SKM Life Sciences Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Critical accounting judgements and key sources of estimation uncertainty
No significant judgements or key assumptions have had to be made by the directors in preparing
these financial statements.

Turnover
Turnover represents net invoiced sales of services, excluding value added tax. Revenue is recognised when services are rendered.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.
Computer equipment - 33% on cost

Financial instruments
The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other debtors, loans from banks and other third parties.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the profit or loss.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate determined under the contract.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and the best estimate, which is an approximation, of the amount the company would receive for the asset if it were to be sold at the reporting date.

Financial assets and liabilities are offset and the net amount reported in the balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


SKM LIFE SCIENCES LIMITED (REGISTERED NUMBER: 10123245)

Notes to the Financial Statements - continued
for the year ended 30 April 2024

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Exchange differences are taken into account in arriving at the operating result.

Unlisted fixed asset investments
The Unlisted Investment is valued at the cost minus impairment.

Leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2023 - 1 ) .

4. TAXATION

Analysis of the tax charge
No liability to UK corporation tax arose for the year ended 30 April 2024 nor for the year ended 30 April 2023.

5. TANGIBLE FIXED ASSETS
Computer
equipment
£   
COST
At 1 May 2023
and 30 April 2024 1,428
DEPRECIATION
At 1 May 2023
and 30 April 2024 1,428
NET BOOK VALUE
At 30 April 2024 -
At 30 April 2023 -

SKM LIFE SCIENCES LIMITED (REGISTERED NUMBER: 10123245)

Notes to the Financial Statements - continued
for the year ended 30 April 2024

6. FIXED ASSET INVESTMENTS
Other
investments
£   
COST
Additions 10,000
At 30 April 2024 10,000
NET BOOK VALUE
At 30 April 2024 10,000

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 2,063 -
Other debtors 564 1,245
2,627 1,245

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Taxation and social security - 76
Other creditors 2,431 840
2,431 916

9. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
100 Ordinary £1 100 100